Biotech News

Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics (TPST)Tempest TherapeuticsEarnings

Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 Secured access to additional capital through an equity line of credit with Lincoln Park Capital Fund of up to $50.0 million and a private

Related news

Tempest Therapeutics

In Vivo CAR-T Platform Tempest Therapeutics is developing targeted lentiviral approaches intended to generate CAR T cells directly inside patients. The strategy seeks to avoid patient-specific ex vivo manufacturing and broaden the use of engineered-cell therapy. TPST-4903 TPST-4903 is the lead in vivo CAR-T candidate from the licensed...

Recent company news

Stock data

Close
0.31 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States